Superior antidepressant efficacy of agomelatine vs fluoxetine in severe major depressive disorder patients: a randomised, double-blind study

被引：5
|
作者：
Hale, A. [1 ]
Corral, R. [2 ]
Mencacci, O. [3 ]
Saiz Ruiz, J. [4 ]
Severo, C. Albarran [5 ]
Gentil, V. [6 ]
机构：
[1] St Martins Hosp, Durham, Kent, England
[2] Ctr Neuropsiquiatria, Buenos Aires, DF, Argentina
[3] Azienda Osped Fatebenefratelli & Oftalm, Milan, Italy
[4] Hosp Ramon & Cajal, E-28034 Madrid, Spain
[5] Inst Rech Int Servier, F-92415 Courbevoie, France
[6] Hosp Clin Sao Paulo, Inst Psiquiatria, Sao Paulo, Brazil
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2009年 / 19卷
关键词：
AGONIST;
D O I：
10.1016/S0924-977X(09)70648-0
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S418 / S419
页数：2
相关论文
共 50 条
  • [1] Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study
    Hale, Anthony
    Corral, Ricardo-Marcelo
    Mencacci, Claudio
    Ruiz, Jeronimo Saiz
    Severo, Cristina Albarran
    Gentil, Valentim
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2010, 25 (06) : 305 - 314
  • [2] Superior antidepressant efficacy of agomelatine versus sertraline: a randomised, double-blind study
    Kasper, S.
    Laigle, L.
    Bayle, F.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S336 - S337
  • [3] Efficacy of agomelatine in elderly patients with major depressive disorder (MDD). Arandomised, double-blind study vs. placebo
    Heun, R.
    Corral, R. M.
    Ahokas, A.
    Nicolini, H.
    Teixeira, J. M.
    Dehelean, P.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 147 - 148
  • [4] Efficacy and safety of agomelatine in patients with major depressive disorder compared to escitalopram: a randomized, double-blind study
    Quera-Salva, M. -A.
    Hajak, G.
    Keufer-Le Gall, S.
    Nutt, D.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 82 - 82
  • [5] Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder
    Nemets, B
    Bersudsky, Y
    Belmaker, RH
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (05) : 586 - 590
  • [6] Reboxetine:: a double-blind comparison with fluoxetine in major depressive disorder
    Massana, J
    Möller, HJ
    Burrows, GD
    Montenegro, RM
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1999, 14 (02) : 73 - 80
  • [7] A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder
    Chouinard, G
    Saxena, B
    Bélanger, MC
    Ravindran, A
    Bakish, D
    Beauclair, L
    Morris, P
    Nair, NPV
    Manchanda, R
    Reesal, R
    Remick, R
    O'Neill, MC
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 1999, 54 (1-2) : 39 - 48
  • [8] Efficacy and safety of agomelatine (25 mg/50 mg), a melatonergic and specific serotonergic antidepressant, in the treatment of major depressive disorder: A randomised, double-blind placebo-controlled study
    Emsley, R
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S350 - S351
  • [9] Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: Randomized, double-blind comparison with venlafaxine
    Lemoine, Patrick
    Guilleminault, Christian
    Alvarez, Enric
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (11) : 1723 - 1732
  • [10] Efficacy of the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients With Major Depressive Disorder: A Randomized, Double-Blind Comparison With Sertraline
    Kasper, Siegfried
    Hajak, Goeran
    Wulff, Katharina
    Hoogendijk, Witte J. G.
    Luis Montejo, Angel
    Smeraldi, Enrico
    Rybakowski, Janusz K.
    Quera-Salva, Maria-Antonia
    Wirz-Justice, Anna M.
    Picarel-Blanchot, Francoise
    Bayle, Franck J.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2010, 71 (02) : 109 - 120
12345